Quick Answer
Artiva Biotherapeutics, Inc. reported Diluted EPS of $3.43 per share (loss) for fiscal year 2025.
Artiva Biotherapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.43 | +41.0% |
| 2024 | -$5.81 | +83.8% |
| 2023 | -$35.78 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.88 | +4.3% | -1.1% |
| June 30, 2025 | -$0.87 | +96.0% | -4.8% |
| March 31, 2025 | -$0.83 | +95.2% | +9.8% |
| September 30, 2024 | -$0.92 | -156.8% | +95.8% |
| June 30, 2024 | -$22.00 | -56.1% | -27.6% |
| March 31, 2024 | -$17.24 | — | -1164.2% |
| September 30, 2023 | $1.62 | — | +111.5% |
| June 30, 2023 | -$14.09 | — | — |
- Artiva Biotherapeutics, Inc. showed an increase of +41.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Artiva Biotherapeutics, Inc.’s diluted eps has grown by 90.4% (from $35.78 per share (loss) to $3.43 per share (loss)).
- The most recent figure is from Artiva Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: